Purpose To assess the intraocular pressure (IOP) changes, within the first 30 min after intravitreal injection of 0.1 ml (4 mg) triamcinolone, 0.09 ml (0.3 mg) pegaptanib, and 0.05 ml (1.25 mg) bevacizumab. Methods Records of patients who received intravitreal triamcinolone, pegaptanib, and bevacizumab and who had their IOP measured post-injection were reviewed. Results A total of 212 injections were performed (76 bevacizumab in 63 patients, 42 triamcinolone in 41 patients, 94 pegaptanib in 74 patients). At 10 min, over 87% of eyes receiving each drug had an IOP of less than 35 mmHg. Three of the 42 eyes receiving intravitreal triamcinolone were treated with IOP-lowering drops for pressures of 44, 46, and 60 mmHg. No patients treated with intravitreal bevacizumab or pegaptanib received IOP-lowering drops. The number of eyes in each injection group that had an IOP rise 410 mmHg within 30 min after injection was 27.6% of eyes receiving bevacizumab, 33.3% of eyes receiving triamcinolone, and 36.2% of eyes receiving pegaptanib. At 10 min, eyes with glaucoma were less likely to have an IOPo35 mmHg, but this difference became less marked with time. Conclusion In our series, most patients receiving intravitreal injections did not require IOP-lowering drops after injection, and none required a paracentesis.
Introduction
Currently used intravitreal drugs for the treatment of retinal diseases include triamcinolone acetonide (Kenalog-40, BristolMyers Squibb, Peapack, NJ, USA), pegaptanib sodium (Macugen, Eyetech-OSI, New York, USA), bevacizumab (Avastin, Genenetech, San Francisco, CA, USA), and ranibizumab (Lucentis, Genentech, San Francisco, CA, USA). The most commonly used doses are 0.1 ml (4 mg) of triamcinolone, 0.09 ml (0.3 mg) of pegaptanib, 0.05 ml (1.25 mg) of bevacizumab, and 0.05 ml (0.5 mg) of ranibizumab. Injecting fluid into the eye transiently increases the intraocular pressure (IOP). The current recommendation for performing intravitreal injections advises against performing a paracentesis. 1 However, in patients who suffer from glaucoma or optic nerve damage, there is a concern that a transient high IOP elevation may further damage the ganglion cells in the optic nerve. It is important to know the transient IOP elevations that patients are subjected to after such intravitreal injections for several reasons, such as to assess whether a paracentesis is necessary, whether IOP monitoring is necessary after the procedure, and to reassess, when manufacturing a new drug, the optimum amount of fluid to be injected into the eye. In our practice at the Mayo Clinic, we have routinely performed and recorded IOPs after intravitreal injection, at various time points, starting 5 min after injection, until the IOP decreases to below 30 mmHg.
Methods
Permission was obtained from the Institutional Review Board of the Mayo Clinic to perform this study. Patients who had received intravitreal injections of triamcinolone acetonide, pegaptanib, or bevacizumab, between July 2005 and December 2005, were identified from a computer database. The records were reviewed and the following data were collected: pre-injection IOP, method of measurement, all-post-injection IOPs and their time points, and whether any glaucoma medications were used to lower the IOP.
Results
A total of 212 injections were performed (76 bevacizumab in 63 patients, 42 triamcinolone in 41 patients, 94 pegaptanib in 74 patients). There were 161 unique patients; each patient may have received more than one injection and may have had injections of more than one type of drug. All pre-injection IOPs were performed by Goldmann applanation tonometry, except 5, which were measured with either the pneumotonometer or the Tono-Pen XL (Medtronic Xomed Ophthalmics, Inc., Minneapolis, MN, USA). All post-injection IOP measurements had been measured using the Tono-Pen XL. Figure 1 shows the mean IOPs for the eyes receiving the three drugs at different time points. IOP measurements were discontinued when the IOP was less than 30 mmHg. All eyes had a pre-injection IOP of less than 35 mmHg. It can be seen that three eyes that received intravitreal triamcinolone had prolonged IOP rises of over 35 mmHg, which had to be monitored. The highest IOP recorded was an IOP of 60 mmHg, 10 min after receiving intravitreal triamcinolone. The patient was treated with brimonidine tartrate 0.15% (Alphagan P, Allergan, Irvine, CA, USA) eye drops, which lowered the IOP to 31 mmHg, 30 min after the drops, and to 21 mmHg, 60 min after the drops. Overall, 3 of the 42 eyes receiving intravitreal triamcinolone were treated with IOP-lowering drops (timolol maleate 0.5%, and/or brimonidine 0.15%) for pressures of 44, 46, and 60 mmHg. No patients treated with intravitreal bevacizumab or pegaptanib received IOP-lowering drops. Table 1 shows the proportion of eyes for each drug injection that had a post-injection pressure of less than or equal to 35 mmHg. At 10 min, over 87% of eyes receiving each drug had an IOP of less than 35 mmHg. There was no statistically significant difference at 10 min between the mean IOPs of each drug (P40.05). At 15 min, over 83% of eyes receiving each drug had an IOP of less than 35 mmHg. Over 90% of eyes in all groups maintained an IOP of less than 35 at all time points measured; there was no statistically significant difference between the mean IOPs of each drug (P40.05) at all time points. Table 2 shows the number of eyes in each injection group that had an IOP rise of greater than 10 mmHg at any time point during the follow-up. This was 27.6% of eyes receiving bevacizumab, 33.3% of eyes receiving triamcinolone, and 36.2% of eyes receiving pegaptanib. There was no statistically significant difference in the number of eyes with an IOP rise of greater than 10 mmHg between the three drugs (P40.05). Table 3 shows the proportion of eyes for each drug injection that had a post-injection pressure of less than or equal to 35 mmHg, depending on whether there was a history of glaucoma. A history of glaucoma was based on whether the patient had a clinical diagnosis or was taking glaucoma drops.
Owing to the overlap of patients receiving more than one injection and injection type, generalized estimating equation models were used when calculating P-values to account for the potential correlation among the eyes from the same patient.
A Kaplan-Meier plot (Figure 2) shows the cumulative probability with time that the IOP attained 30 mmHg or less. Figure 3 is a Kaplan-Meier plot showing the cumulative probability with time that the IOP attained 30 mmHg or less, in patients with glaucoma vs no glaucoma.
Discussion
There is individual variation in IOP elevation after the injection of the same amount of drug. This variation is Table 2 The number of eyes in each injection group that had an IOP rise of greater than 10 mmHg at any time point during the follow-up
Rise in intraocular pressure at any time point measured Intravitreal drug due to relative inaccuracy of dosing exactly the intended amount in a clinical setting. In addition, scleral rigidity differs between patients. Another source of variation is whether there is reflux from the injection site after the needle is withdrawn. 2 Larger needles may allow more reflux from the injection site, and therefore a lower immediate IOP. We use 31-gauge needles to inject bevacizumab, 27-gauge needles for triamcinolone, and the prepackaged 27-gauge needles for pegaptanib. 3 In our series, anterior chamber paracentesis was not necessary after the intravitreal injections. A review of IOPs in 122 eyes, after intravitreal pegaptanib injection, into groups depending on whether they had glaucoma. Our results show that at 10 min, across all injection types, eyes with glaucoma were less likely (Po0.05) to have an IOP lower than 35 mmHg. This difference became less significant with time ( Figure 3) .
Knowledge of the IOP fluctuations after intravitreal injection allows ophthalmologists to make a clinical judgment regarding whether a patient with glaucomatous optic nerve damage may benefit from an anterior chamber paracentesis to avoid the damage associated with repeated episodes of high IOP.
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